IL1B and metabolic dysfunction-associated steatotic liver disease: The discovery that LITAF is a main regulator of IL-1β in HSCs could provide a new mechanism that may improve both our understanding of how NAFLD-related liver damage (i.e. inflammation and fibrosis) develops, and the design of novel therapeutic approaches.